MDS Responds to AECL and Government of Canada Announcements Regarding Maple Project
16 Mai 2008 - 7:12PM
PR Newswire (US)
TORONTO, May 16 /PRNewswire-FirstCall/ -- Earlier this morning,
Atomic Energy of Canada Ltd. (AECL) announced it would discontinue
the development of the MAPLE reactors at Chalk River, but remains
committed to providing ongoing supply of medical isotopes. MDS
Inc., a leading provider of products and services to the global
life sciences markets, was not consulted by AECL about this
decision, and the company is evaluating these developments. MDS
Nordion, a business unit of MDS, is a leading provider of medical
isotopes and radiopharmaceuticals. "The most important issue has
always been the continuity of medical isotope supply for patients
worldwide," said Stephen P. DeFalco, President and CEO, MDS Inc.
"We are pleased that the government has asked AECL to pursue the
extension of the NRU operation beyond its current license and to
ensure the ongoing supply of these critical medical isotopes." MDS
is disappointed that AECL has stated it will not complete the MAPLE
project despite significant investment and effort over the past 12
years. The company will evaluate all options and pursue appropriate
steps to protect the interests of patients, its customers and its
shareholders. About MDS MDS Inc. (TSX: MDS; NYSE: MDZ) is a global
life sciences company that provides market-leading products and
services that our customers need for the development of drugs and
the diagnosis and treatment of disease. We are a leading global
provider of pharmaceutical contract research, medical isotopes for
molecular imaging, radiotherapeutics, and analytical instruments.
MDS has more than 5,500 highly skilled people in 29 countries. Find
out more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day. DATASOURCE: MDS Inc. CONTACT: For Media, Janet Ko, MDS
Inc., (416) 213-4167, ; For Investors, Kim Lee, MDS Inc., (416)
675-6777 x32606,
Copyright